肾上腺皮质腺癌诊治进展

肾上腺皮质腺癌临床较罕见,由于肿瘤进展速度快、早期诊断困难,患者预后通常不佳.近年来随着影像学与分子生物学技术发展,肾上腺皮质腺癌的早期诊断率得到很大提高;其治疗仍以手术根治为主,各种姑息性治疗也有较大发展.现综述肾上腺皮质腺癌诊治最新进展.     

肾上腺皮质腺癌1例

肾上腺皮质癌较为罕见,2000年3月我院诊治1例,现报告如下: 患者女,50岁,右侧腰部胀痛不适、肢体无力3个月,于2000年3月5日拟“右肾上腺肿瘤”入院。查体:BP18/12kPa,满月脸,呈向中心肥胖体态,血清钾3.27mmol/L,晨     

肾上腺皮质腺癌临床分析

目的：分析原发性肾上腺皮质腺癌的治疗及预后。方法：分析21例肾上腺皮质腺癌的临床资料。结果：术后随访1-5年，生存2年以上11例（52．4％），5年以上5例（23．8％）。结论：肾上腺皮质腺癌预后差，早期诊断、及时手术是目前治疗肾上腺皮质腺癌最有效的方法。     

肾上腺皮质腺癌的分子诊治研究进展

检索关于肾上腺皮质肿瘤分子生物学的相关报道,进行分析汇总。搜索出大量相关文献,分别在差异基因、甲基化、基因突变、microRNAs、LncRNAs等方面获得不同的研究进展。通过肿瘤分子生物学,可对疾病进行早期鉴别诊断与治疗,改善并提高肾上腺皮质腺癌患者的预后与生存质量。     

肾上腺皮质腺癌20例临床分析

目的分析原发性肾上腺皮质腺癌的治疗及预后。方法回顾1965年至1998年间20例肾上腺皮质腺癌术后±局部放疗或化疗的存活情况。结果18例行根治性手术,2例行姑息性手术;术后6例接受放疗,3例接受化疗。随访至1998年12月,仅1例存28年。结论肾上腺皮质腺癌应早期手术。术后辅以米托坦治疗有望改善存活。     

构建人类肾上腺皮质腺癌细胞系并用其验证过继免疫细胞治疗效果

 目的　建立人类肾上腺皮质腺癌（ACC）细胞系ACC-LWL,研究其表型及肿瘤相关抗原表达,并以此模型初步探讨过继免疫细胞治疗ACC的可行性。方法　手术获得的ACC的新鲜肿瘤组织经体外原代和传代培养至稳定生长,分析其生物学特征,包括癌细胞集落形成、染色体及成瘤性,经流式细胞术分析细胞系细胞表型,RT-PCR检测MN／CA9和HLA-A2基因表达。体外用IL-2（200 U／ml）和ACC-LWL冻融抗原（20 μg／ml）共同刺激异体人单个核细胞（PBMC）产生细胞毒性T淋巴细胞（CTL）,通过流式细胞术分析异体人CTL的CD3、CD4、CD8表达水平,检测CTL对ACC-LWL肿瘤细胞的杀伤作用。结果　ACC-LWL表现恶性肿瘤细胞的生物特性,能于裸鼠体内成瘤,细胞高表达MHC-I,低表达Her-2／neu和MHC-Ⅱ,不表达CD80和CD86。ACC-LWL表达MN／CA9和HLA-A2基因。从HLA-A2+和HLA-A3+供体获得的CTL均显示杀伤ACC-LWL,未见HLA限制性杀伤。结论　成功建立ACC细胞系ACC-LWL,可提供用于研究人类ACC的细胞及动物模型,为过继免疫细胞治疗在ACC中的应用提供初步的实验依据。     

肾上腺皮质腺癌五例报告

肾上腺皮质腺癌五例报告山东省肿瘤防治研究院（济南市２５０１１７）赵献光于素娟衣龙海张鑫石学涛肾上腺皮质腺癌临床较为少见，我院自１９９１年６月～１９９７年２月共收治５例，均经手术病理检查诊断，现报告如下。１临床资料本组５例，男３例，女２例，年龄４０～５...     

构建人类肾上腺皮质腺癌细胞系并用其验证过继免疫细胞治疗效果

Objective To establish a human adrenocortical carcinoma (ACC)cell line ACC-LWL, and investigate its cell phenotypes and expression of tumor associated antigens, to detect sensitivity of ACC-LWL against adoptive immune cells. Methods Fresh tumor tissues from the resection of a human ACC were primary cultured and passed generation to generation so as to achieve stable growth in vitro. For analyzing its biological characteristic, the cell cloning formation in soft agar, chromosome and tumorigenesis were tested. Flow cytometric analysis was carried out for phenotype analysis and RT-PCR examination for MN/CA9 and HLA-A2 genes expression. PBMC from 4 healthy donors (2 HLA-A2+ or 2 HLA-A3+) co-cultured with IL-2 (200 U/ml)and the tumor cell lysate of ACC-LWL (20 μg/ml) in vitro to generate CTL. After 14 day stimulation, CTLs were incubated with ACC-LWL with a E/T ratio of 10:1 for 4 hours at 37 ℃. Cytotoxicity was measured with MTr assay. Results One human ACC cell line had been established that showed the characteristics of malignant cells. The cells grew a solid tumor in nude mice. ACC-LWL had a high expression of MHC-Ⅰ, weakly expression of Her2/neu and MHC-Ⅱ, no expression of CD80 or CD86. RT-PCR showed that ACC-LWL expressed MN/CA9 and HLA-A2 genes. CTL, either HLA-A2+ or HLA-A3+, had the capability of killing ACC-LWL in vitro. Conclusion This newly established ACC would provide a useful target in vitro and in vivo for investigations related to human ACC.     

构建人类肾上腺皮质腺癌细胞系并用其验证过继免疫细胞治疗效果

Objective To establish a human adrenocortical carcinoma (ACC)cell line ACC-LWL, and investigate its cell phenotypes and expression of tumor associated antigens, to detect sensitivity of ACC-LWL against adoptive immune cells. Methods Fresh tumor tissues from the resection of a human ACC were primary cultured and passed generation to generation so as to achieve stable growth in vitro. For analyzing its biological characteristic, the cell cloning formation in soft agar, chromosome and tumorigenesis were tested. Flow cytometric analysis was carried out for phenotype analysis and RT-PCR examination for MN/CA9 and HLA-A2 genes expression. PBMC from 4 healthy donors (2 HLA-A2+ or 2 HLA-A3+) co-cultured with IL-2 (200 U/ml)and the tumor cell lysate of ACC-LWL (20 μg/ml) in vitro to generate CTL. After 14 day stimulation, CTLs were incubated with ACC-LWL with a E/T ratio of 10:1 for 4 hours at 37 ℃. Cytotoxicity was measured with MTr assay. Results One human ACC cell line had been established that showed the characteristics of malignant cells. The cells grew a solid tumor in nude mice. ACC-LWL had a high expression of MHC-Ⅰ, weakly expression of Her2/neu and MHC-Ⅱ, no expression of CD80 or CD86. RT-PCR showed that ACC-LWL expressed MN/CA9 and HLA-A2 genes. CTL, either HLA-A2+ or HLA-A3+, had the capability of killing ACC-LWL in vitro. Conclusion This newly established ACC would provide a useful target in vitro and in vivo for investigations related to human ACC.     

构建人类肾上腺皮质腺癌细胞系并用其验证过继免疫细胞治疗效果

Objective To establish a human adrenocortical carcinoma (ACC)cell line ACC-LWL, and investigate its cell phenotypes and expression of tumor associated antigens, to detect sensitivity of ACC-LWL against adoptive immune cells. Methods Fresh tumor tissues from the resection of a human ACC were primary cultured and passed generation to generation so as to achieve stable growth in vitro. For analyzing its biological characteristic, the cell cloning formation in soft agar, chromosome and tumorigenesis were tested. Flow cytometric analysis was carried out for phenotype analysis and RT-PCR examination for MN/CA9 and HLA-A2 genes expression. PBMC from 4 healthy donors (2 HLA-A2+ or 2 HLA-A3+) co-cultured with IL-2 (200 U/ml)and the tumor cell lysate of ACC-LWL (20 μg/ml) in vitro to generate CTL. After 14 day stimulation, CTLs were incubated with ACC-LWL with a E/T ratio of 10:1 for 4 hours at 37 ℃. Cytotoxicity was measured with MTr assay. Results One human ACC cell line had been established that showed the characteristics of malignant cells. The cells grew a solid tumor in nude mice. ACC-LWL had a high expression of MHC-Ⅰ, weakly expression of Her2/neu and MHC-Ⅱ, no expression of CD80 or CD86. RT-PCR showed that ACC-LWL expressed MN/CA9 and HLA-A2 genes. CTL, either HLA-A2+ or HLA-A3+, had the capability of killing ACC-LWL in vitro. Conclusion This newly established ACC would provide a useful target in vitro and in vivo for investigations related to human ACC.     

构建人类肾上腺皮质腺癌细胞系并用其验证过继免疫细胞治疗效果

Objective To establish a human adrenocortical carcinoma (ACC)cell line ACC-LWL, and investigate its cell phenotypes and expression of tumor associated antigens, to detect sensitivity of ACC-LWL against adoptive immune cells. Methods Fresh tumor tissues from the resection of a human ACC were primary cultured and passed generation to generation so as to achieve stable growth in vitro. For analyzing its biological characteristic, the cell cloning formation in soft agar, chromosome and tumorigenesis were tested. Flow cytometric analysis was carried out for phenotype analysis and RT-PCR examination for MN/CA9 and HLA-A2 genes expression. PBMC from 4 healthy donors (2 HLA-A2+ or 2 HLA-A3+) co-cultured with IL-2 (200 U/ml)and the tumor cell lysate of ACC-LWL (20 μg/ml) in vitro to generate CTL. After 14 day stimulation, CTLs were incubated with ACC-LWL with a E/T ratio of 10:1 for 4 hours at 37 ℃. Cytotoxicity was measured with MTr assay. Results One human ACC cell line had been established that showed the characteristics of malignant cells. The cells grew a solid tumor in nude mice. ACC-LWL had a high expression of MHC-Ⅰ, weakly expression of Her2/neu and MHC-Ⅱ, no expression of CD80 or CD86. RT-PCR showed that ACC-LWL expressed MN/CA9 and HLA-A2 genes. CTL, either HLA-A2+ or HLA-A3+, had the capability of killing ACC-LWL in vitro. Conclusion This newly established ACC would provide a useful target in vitro and in vivo for investigations related to human ACC.     

构建人类肾上腺皮质腺癌细胞系并用其验证过继免疫细胞治疗效果

Objective To establish a human adrenocortical carcinoma (ACC)cell line ACC-LWL, and investigate its cell phenotypes and expression of tumor associated antigens, to detect sensitivity of ACC-LWL against adoptive immune cells. Methods Fresh tumor tissues from the resection of a human ACC were primary cultured and passed generation to generation so as to achieve stable growth in vitro. For analyzing its biological characteristic, the cell cloning formation in soft agar, chromosome and tumorigenesis were tested. Flow cytometric analysis was carried out for phenotype analysis and RT-PCR examination for MN/CA9 and HLA-A2 genes expression. PBMC from 4 healthy donors (2 HLA-A2+ or 2 HLA-A3+) co-cultured with IL-2 (200 U/ml)and the tumor cell lysate of ACC-LWL (20 μg/ml) in vitro to generate CTL. After 14 day stimulation, CTLs were incubated with ACC-LWL with a E/T ratio of 10:1 for 4 hours at 37 ℃. Cytotoxicity was measured with MTr assay. Results One human ACC cell line had been established that showed the characteristics of malignant cells. The cells grew a solid tumor in nude mice. ACC-LWL had a high expression of MHC-Ⅰ, weakly expression of Her2/neu and MHC-Ⅱ, no expression of CD80 or CD86. RT-PCR showed that ACC-LWL expressed MN/CA9 and HLA-A2 genes. CTL, either HLA-A2+ or HLA-A3+, had the capability of killing ACC-LWL in vitro. Conclusion This newly established ACC would provide a useful target in vitro and in vivo for investigations related to human ACC.     

构建人类肾上腺皮质腺癌细胞系并用其验证过继免疫细胞治疗效果

Objective To establish a human adrenocortical carcinoma (ACC)cell line ACC-LWL, and investigate its cell phenotypes and expression of tumor associated antigens, to detect sensitivity of ACC-LWL against adoptive immune cells. Methods Fresh tumor tissues from the resection of a human ACC were primary cultured and passed generation to generation so as to achieve stable growth in vitro. For analyzing its biological characteristic, the cell cloning formation in soft agar, chromosome and tumorigenesis were tested. Flow cytometric analysis was carried out for phenotype analysis and RT-PCR examination for MN/CA9 and HLA-A2 genes expression. PBMC from 4 healthy donors (2 HLA-A2+ or 2 HLA-A3+) co-cultured with IL-2 (200 U/ml)and the tumor cell lysate of ACC-LWL (20 μg/ml) in vitro to generate CTL. After 14 day stimulation, CTLs were incubated with ACC-LWL with a E/T ratio of 10:1 for 4 hours at 37 ℃. Cytotoxicity was measured with MTr assay. Results One human ACC cell line had been established that showed the characteristics of malignant cells. The cells grew a solid tumor in nude mice. ACC-LWL had a high expression of MHC-Ⅰ, weakly expression of Her2/neu and MHC-Ⅱ, no expression of CD80 or CD86. RT-PCR showed that ACC-LWL expressed MN/CA9 and HLA-A2 genes. CTL, either HLA-A2+ or HLA-A3+, had the capability of killing ACC-LWL in vitro. Conclusion This newly established ACC would provide a useful target in vitro and in vivo for investigations related to human ACC.     

构建人类肾上腺皮质腺癌细胞系并用其验证过继免疫细胞治疗效果

Objective To establish a human adrenocortical carcinoma (ACC)cell line ACC-LWL, and investigate its cell phenotypes and expression of tumor associated antigens, to detect sensitivity of ACC-LWL against adoptive immune cells. Methods Fresh tumor tissues from the resection of a human ACC were primary cultured and passed generation to generation so as to achieve stable growth in vitro. For analyzing its biological characteristic, the cell cloning formation in soft agar, chromosome and tumorigenesis were tested. Flow cytometric analysis was carried out for phenotype analysis and RT-PCR examination for MN/CA9 and HLA-A2 genes expression. PBMC from 4 healthy donors (2 HLA-A2+ or 2 HLA-A3+) co-cultured with IL-2 (200 U/ml)and the tumor cell lysate of ACC-LWL (20 μg/ml) in vitro to generate CTL. After 14 day stimulation, CTLs were incubated with ACC-LWL with a E/T ratio of 10:1 for 4 hours at 37 ℃. Cytotoxicity was measured with MTr assay. Results One human ACC cell line had been established that showed the characteristics of malignant cells. The cells grew a solid tumor in nude mice. ACC-LWL had a high expression of MHC-Ⅰ, weakly expression of Her2/neu and MHC-Ⅱ, no expression of CD80 or CD86. RT-PCR showed that ACC-LWL expressed MN/CA9 and HLA-A2 genes. CTL, either HLA-A2+ or HLA-A3+, had the capability of killing ACC-LWL in vitro. Conclusion This newly established ACC would provide a useful target in vitro and in vivo for investigations related to human ACC.     

构建人类肾上腺皮质腺癌细胞系并用其验证过继免疫细胞治疗效果

Objective To establish a human adrenocortical carcinoma (ACC)cell line ACC-LWL, and investigate its cell phenotypes and expression of tumor associated antigens, to detect sensitivity of ACC-LWL against adoptive immune cells. Methods Fresh tumor tissues from the resection of a human ACC were primary cultured and passed generation to generation so as to achieve stable growth in vitro. For analyzing its biological characteristic, the cell cloning formation in soft agar, chromosome and tumorigenesis were tested. Flow cytometric analysis was carried out for phenotype analysis and RT-PCR examination for MN/CA9 and HLA-A2 genes expression. PBMC from 4 healthy donors (2 HLA-A2+ or 2 HLA-A3+) co-cultured with IL-2 (200 U/ml)and the tumor cell lysate of ACC-LWL (20 μg/ml) in vitro to generate CTL. After 14 day stimulation, CTLs were incubated with ACC-LWL with a E/T ratio of 10:1 for 4 hours at 37 ℃. Cytotoxicity was measured with MTr assay. Results One human ACC cell line had been established that showed the characteristics of malignant cells. The cells grew a solid tumor in nude mice. ACC-LWL had a high expression of MHC-Ⅰ, weakly expression of Her2/neu and MHC-Ⅱ, no expression of CD80 or CD86. RT-PCR showed that ACC-LWL expressed MN/CA9 and HLA-A2 genes. CTL, either HLA-A2+ or HLA-A3+, had the capability of killing ACC-LWL in vitro. Conclusion This newly established ACC would provide a useful target in vitro and in vivo for investigations related to human ACC.     

构建人类肾上腺皮质腺癌细胞系并用其验证过继免疫细胞治疗效果

Objective To establish a human adrenocortical carcinoma (ACC)cell line ACC-LWL, and investigate its cell phenotypes and expression of tumor associated antigens, to detect sensitivity of ACC-LWL against adoptive immune cells. Methods Fresh tumor tissues from the resection of a human ACC were primary cultured and passed generation to generation so as to achieve stable growth in vitro. For analyzing its biological characteristic, the cell cloning formation in soft agar, chromosome and tumorigenesis were tested. Flow cytometric analysis was carried out for phenotype analysis and RT-PCR examination for MN/CA9 and HLA-A2 genes expression. PBMC from 4 healthy donors (2 HLA-A2+ or 2 HLA-A3+) co-cultured with IL-2 (200 U/ml)and the tumor cell lysate of ACC-LWL (20 μg/ml) in vitro to generate CTL. After 14 day stimulation, CTLs were incubated with ACC-LWL with a E/T ratio of 10:1 for 4 hours at 37 ℃. Cytotoxicity was measured with MTr assay. Results One human ACC cell line had been established that showed the characteristics of malignant cells. The cells grew a solid tumor in nude mice. ACC-LWL had a high expression of MHC-Ⅰ, weakly expression of Her2/neu and MHC-Ⅱ, no expression of CD80 or CD86. RT-PCR showed that ACC-LWL expressed MN/CA9 and HLA-A2 genes. CTL, either HLA-A2+ or HLA-A3+, had the capability of killing ACC-LWL in vitro. Conclusion This newly established ACC would provide a useful target in vitro and in vivo for investigations related to human ACC.     

构建人类肾上腺皮质腺癌细胞系并用其验证过继免疫细胞治疗效果

Objective To establish a human adrenocortical carcinoma (ACC)cell line ACC-LWL, and investigate its cell phenotypes and expression of tumor associated antigens, to detect sensitivity of ACC-LWL against adoptive immune cells. Methods Fresh tumor tissues from the resection of a human ACC were primary cultured and passed generation to generation so as to achieve stable growth in vitro. For analyzing its biological characteristic, the cell cloning formation in soft agar, chromosome and tumorigenesis were tested. Flow cytometric analysis was carried out for phenotype analysis and RT-PCR examination for MN/CA9 and HLA-A2 genes expression. PBMC from 4 healthy donors (2 HLA-A2+ or 2 HLA-A3+) co-cultured with IL-2 (200 U/ml)and the tumor cell lysate of ACC-LWL (20 μg/ml) in vitro to generate CTL. After 14 day stimulation, CTLs were incubated with ACC-LWL with a E/T ratio of 10:1 for 4 hours at 37 ℃. Cytotoxicity was measured with MTr assay. Results One human ACC cell line had been established that showed the characteristics of malignant cells. The cells grew a solid tumor in nude mice. ACC-LWL had a high expression of MHC-Ⅰ, weakly expression of Her2/neu and MHC-Ⅱ, no expression of CD80 or CD86. RT-PCR showed that ACC-LWL expressed MN/CA9 and HLA-A2 genes. CTL, either HLA-A2+ or HLA-A3+, had the capability of killing ACC-LWL in vitro. Conclusion This newly established ACC would provide a useful target in vitro and in vivo for investigations related to human ACC.     

肾上腺皮质癌诊治的现状和进展

肾上腺皮质癌（adrenocortical carcinoma,ACC）是原发于肾上腺皮质的恶性肿瘤,临床上较罕见,发病率仅为0．5／100万～2．0／100万,占所有恶性肿瘤的0．02％,占肾上腺偶发瘤的4．7％～14％。肾上腺皮质癌恶性程度高,侵袭性强,早期确诊率不高,其治疗仍以根治手术为主,缺乏有效的辅助治疗,术后复发率、远处转移发生率高,预后较差,平均生存期只有18个月。     

小肠腺癌诊治进展

小肠腺癌（smal lbowel adenocarcinoma,SBA ）是一种预后不良,发病率增加,且比较少见的肿瘤。该疾病常被延误诊断,大多数患者确诊时已为晚期。由于缺乏随机对照研究数据,临床治疗决策较为困难。根治性手术通常认为是必要的。辅助化疗预计是有益的,但仍未被随机研究结果证实。对于晚期SBA 患者,回顾性研究表明以铂类为基础的化疗方案似乎最有效。靶向治疗仍缺乏足够数据支持。本文综述SBA 的诊断与治疗进展。      

胸腺癌的临床诊治进展

胸腺癌是发病率较低的胸腺上皮肿瘤,较为罕见,侵袭力强,恶性程度高,但临床表现缺乏特征性,术前诊断与恶性胸腺瘤鉴别困难。治疗多采取手术、放疗、化疗的综合治疗,完整切除是最有效的治疗手段,辅助治疗方案多样化,缺乏规范和共识。本文对近年来胸腺癌的分类、分期、分子特征以及临床诊治进展作一综述。